Abeona Therapeutics Inc. (ABEO) 12-Month Stock Forecast & Price Target Cone

Per the Roarable RQD rating, ABEO carries an RQD Score of 23 out of 100, letter grade E, with the verdict label "Roarable Strong Sell — Forensic Risk / Avoid." Across the five pillars, the fundamental cash engine scores 4 of 20 (ROIC -35%; FCF yield 0%), indicating the business is not currently generating returns on capital or free cash flow. Whale 13F flow scores 3 of 20 and insider conviction scores 3 of 20, meaning the rating reads institutional accumulation, options positioning, Form 4 and Congressional PTR flows as weak. Macro regime fit scores 8 of 20 with a beta of 1.0. Forensic balance sheet scores 5 of 20, reflecting an Altman Z of 0.2, Piotroski F of 3/9, and Debt/Equity of 0.05. For a prospective investor, the implications are that the low debt load is offset by severe operating losses and a weak distress signal, so any upside would have to come from a catalyst the current cash engine does not yet support. Valuation tradeoffs cannot be fully assessed because P/E, forward P/E, and EV/EBITDA are not available in source data.

Per the SEC financials, operating margin and net margin are both -60% and gross margin is 73.7%, with ROIC at -35%. Reported net income is negative in FY 2025 at $-71.2M but positive in FY 2024 at $63.7M while operating income was $-64.2M, a divergence the source does not explain. The Altman Z-Score is 0.2 and the Piotroski F-Score is 3/9, both per the Roarable RQD rating. Debt/Equity is 0.05 and cash stood at $78.4M in FY 2025 against debt of $7.8M.

Per the recent news wire, the items are: a TradingView estimates report; a MarketScreener report on James Russell engaging and pushing for board and leadership changes at Abeona Therapeutics (flagged yellow); a Yahoo! Finance Canada seasonal returns chart for a related issuer; a Simply Wall St piece titled "High Growth Stocks With Strong Insider Confidence" (flagged green as a catalyst); a Manila Times report on employee inducement grants under Nasdaq Listing Rule 5635(c)(4); and a Pluang item on OS Therapies appointing Rubenstein PR. The leadership-change engagement is the most material risk watch item, while the insider-confidence headline is the only item tagged as a catalyst; the source does not state the underlying facts of either beyond headlines. The Butterfly supply-chain graph reports no supply chain and no proprietary signals.

• What is the business model and product pipeline that produces the reported $5.8M FY 2025 revenue?
• What explains the positive FY 2024 net income of $63.7M against an operating loss of $-64.2M?
• What are the terms and outcome of the leadership-change engagement referenced in the news wire?
• Why are FY 2023 cash and debt not reported, and how does the FY 2025 cash balance of $78.4M compare to cash burn implied by FCF of $-84.3M?
• What are the P/E, forward P/E, and EV/EBITDA metrics once earnings are positive, if ever?